ALX Oncology Holdings Inc (ALXO): Free Cash Flow
-$84.35M
Year ended 2025-12-31
-$70.95M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$84.35M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$122.36M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$131.64M | n/m | 2026-03-09, From 2023-01-01 |
| 2022-12-31 | -$90.65M | n/m | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | -$68.77M | n/m | 2024-03-07, From 2021-01-01 |
| 2020-12-31 | -$38.32M | n/m | 2023-03-09, From 2020-01-01 |
| 2019-12-31 | -$14.60M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$13.84M | n/a | 2021-03-18, From 2018-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | -$84.35M | n/m |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | -$18.80M | n/m |
| Biomea Fusion, Inc. (BMEA) | 2024-12-31 | -$120.26M | n/m |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | -$8.34M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$1.20M | n/m |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | -$29.10M | n/m |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | -$39.92M | n/m |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | -$33.54M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $6.67M | -36.5% |
Compare ALXO, RANI, BMEA, PRPH side by side · Screen every company in Pharmaceutical Preparations ↗